Paper
RSC Advances
124.3, 124.2, 123.9, 122.5, 119.5, 117.7, 113.8, 108.7; anal. calcd
for C14H8Br2N4O2: C, 39.65; H, 1.90; N, 13.21. Found: C, 39.58;
H, 1.90; N, 13.19%.
2-Methylbenzo[b]thiophen-3-ylboronic acid (5). White solid,
800 mg, 29%; 1H NMR (400 MHz, d6-DMSO): d 8.14 (s, 1H), 7.91
(d, J ¼ 8.0 Hz, 1H), 7.82 (d, J ¼ 8.0 Hz, 1H), 7.92 (td, J ¼ 8.4, 1.2
Hz, 1H), 7.22 (td, J ¼ 8.4, 1.2 Hz, 1H), 2.64 (s, 3H).
L1–L5 were prepared by the cross-coupling reaction of the
corresponding boronic acid with 1-aryl-4,5-dibromo-2-(2-pyr-
idyl)imidazole according to the standard Suzuki coupling
procedure under an inert atmosphere of argon. Aqueous
Cs2CO3 solution (2 M, 5 mL, 10 mmol) was added to a vigorously
stirred solution of the corresponding boronic acid (2.5 mmol),
1-aryl-4,5-dibromo-2-(2-pyridyl)imidazole (1 mmol), Pd(PPh3)4
(0.1 mmol) in dioxane (20 mL) under reux. And the course of
the reaction was monitored by TLC. Aer the reaction nished,
the mixture was extracted with ethyl acetate. The combined
extracts were dried over anhydrous magnesium sulfate. Then
ltration and removal of the solvent in vacuum, the crude
product was puried by silica gel column chromatography to
give the corresponding product.
Compounds 9–11 were synthesized by a slight modication
of the literature procedures.37 2-(2-Pyridyl)imidazole (30 mmol),
halogenobenzene (50 mmol), CuI (10 mmol), 1,10-phenan-
throline (20 mmol) and Cs2CO3 (45 mmol) were dissolved in
anhydrous DMF (120 mL) under reux in an inert atmosphere
of argon for 30 h. Then the solvent was removed in vacuum, and
the crude product was puried by silica gel column chroma-
tography to give the corresponding product.
1-(4-Methoxyphenyl)-2-(2-pyridyl)imidazole (9). White solid,
7.3 g, 97%, mp 94–95 ꢀC; 1H NMR (400 MHz, CDCl3): d 7.66–7.68
(m, 1H), 7.43–7.45 (m, 1H), 7.35–7.38 (m, 2H), 7.25 (t, J ¼ 2.0 Hz,
1H), 7.12–7.21 (m, 2H), 6.98–7.00 (m, 2H), 6.63–6.65 (m, 1H),
3.83 (s, 3H); 13C NMR (100 MHz, CDCl3): d 158.2, 136.3, 128.9,
128.2, 125.9, 122.1, 121.0, 120.0, 114.7, 110.3, 102.8, 55.5; anal.
calcd for C15H13N3O: C, 71.70; H, 5.21; N, 16.72. Found: C,
71.65; H, 5.21; N, 16.70%.
1-(4-Methoxyphenyl)-4,5-bis-[5-chloro-2-methyl-3-thienyl]-2-
(2-pyridyl)imidazole (L1). White solid, 400 mg, 78%, mp 114–
1
ꢀ
115 C; H NMR (400 MHz, CDCl3): d 8.35 (d, J ¼ 4.0 Hz, 1H),
7.94 (d, J ¼ 8.0 Hz, 1H), 7.67–7.72 (m, 1H), 7.14–7.17 (m, 1H),
7.03–7.05 (m, 1H), 6.84–6.92 (m, 2H), 6.73 (d, J ¼ 1.6 Hz, 2H),
6.34 (s, 1H), 3.83 (s, 3H), 2.28 (s, 3H), 1.95 (s, 3H); 13C NMR (100
MHz, CDCl3): d 156.3, 148.7, 146.0, 138.3, 136.3, 134.9, 134.7,
133.1, 130.6, 129.9, 128.5, 127.7, 127.3, 126.2, 126.0, 125.2,
124.8, 124.6, 123.8, 122.8, 110.7, 55.7, 14.3, 13.9; MS (EI): m/z
(%): 515, 513, 511 (M+). Anal. calcd for C25H19Cl2N3OS2: C,
58.59; H, 3.74; N, 8.20. Found: C, 58.37; H, 3.75; N, 8.17%.
1-Phenyl-4,5-bis-[2-methylbenzo[b]thiophen-3-yl]-2-(2-pyr-
idyl)imidazole (L2). White solid, 200 mg, 39%, mp 201–202 ꢀC;
1H NMR (400 MHz, CDCl3): d 8.35–8.36 (m, 1H), 8.03 (d, J ¼ 8.0
Hz, 1H), 7.84–7.86 (m, 1H), 7.72 (td, J ¼ 8.0, 2.0 Hz, 1H), 7.65–
7.67 (m, 1H), 7.56 (d, J ¼ 8.0 Hz, 1H), 6.98–7.25 (m, 11H), 2.10 (s,
3H), 2.04 (s, 3H); 13C NMR (100 MHz, CDCl3): d 149.8, 148.7,
141.7, 140.4, 139.3, 138.6, 138.1, 137.6, 136.3, 128.3, 127.6,
127.1, 124.1, 124.0, 123.9, 123.6, 123.4, 123.1, 122.8, 122.2,
122.0, 121.6, 121.5, 14.9; MS (EI): m/z (%): 513 (M+). Anal. calcd
for C32H23N3S2: C, 74.82; H, 4.51; N, 8.18. Found: C, 74.69; H,
4.52; N, 8.15%.
1-Phenyl-2-(2-pyridyl)imidazole (10). White solid, 6.3 g, 94%
[lit.37 68%], mp 65–66 C.
ꢀ
1-(4-Nitrophenyl)-2-(2-pyridyl)imidazole (11). Yellow solid,
6.1 g, 76%, mp 122–123 ꢀC; 1H NMR (400 MHz, CDCl3): d 8.25–
8.29 (m, 2H), 8.22–8.24 (m, 1H), 8.11 (d, J ¼ 8.0 Hz, 1H), 7.77 (td,
J ¼ 8.0, 2.0 Hz, 1H), 7.41–7.45 (m, 2H), 7.32 (d, J ¼ 1.2 Hz, 1H),
7.17–7.20 (m, 2H); 13C NMR (150 MHz, CDCl3): d 148.9, 148.3,
146.7, 145.3, 144.7, 136.7, 129.8, 126.6, 124.2, 123.6, 123.2,
123.0; anal. calcd for C14H10N4O2: C, 63.15; H, 3.79; N, 21.04.
Found: C, 63.08; H, 3.80; N, 21.01%.
Compounds 12–14 were prepared by modication of a
literature method.38 To a solution of 1-aryl-2-(2-pyridyl)imid-
azole (20 mmol) in CHC13 (350 mL), Br2 (50 mmol) in CHC13 (15
mL) was added dropwise with stirring at room temperature.
Aer reaction for 2 h under reux, the resulting solid was
ltered and washed with aqueous NaHSO3 solution. The
residue was puried by column chromatography on silica gel to
afford the corresponding product.
1-(4-Methoxyphenyl)-4,5-dibromo-2-(2-pyridyl)imidazole (12).
1
ꢀ
1-Phenyl-4,5-bis-[5-chloro-2-methyl-3-thienyl]-2-(2-pyridyl)-
White solid, 8.0 g, 98%, mp 122–123 C; H NMR (400 MHz, d6-
DMSO): d 8.25–8.26 (m, 1H), 7.81–7.87 (m, 2H), 7.24–7.31 (m, 3H),
6.99–7.02 (m, 2H), 3.81 (s, 3H).
1
ꢀ
imidazole (L3). White solid, 338 mg, 70%, mp 123–124 C; H
NMR (400 MHz, CDCl3): d 8.30 (d, J ¼ 4.4 Hz, 1H), 7.90 (d, J ¼ 7.6
Hz, 1H), 7.67 (td, J ¼ 8.0, 2.0 Hz, 1H), 7.28–7.32 (m, 3H), 7.12–7.15
(m, 1H), 7.05–7.07 (m, 2H), 6.74 (s, 1H), 6.27 (s, 1H), 2.28 (s, 3H),
1.93 (s, 3H); 13C NMR (100 MHz, CDCl3): d 149.4, 148.7, 145.8,
138.2, 137.4, 136.2, 135.9, 134.9, 130.5, 128.7, 128.1, 127.6, 127.4,
126.3, 126.0, 125.8, 125.1, 123.7, 122.8, 14.3, 13.9; MS (EI): m/z (%):
485, 483, 481 (M+). Anal. calcd for C24H17Cl2N3S2: C, 59.75; H, 3.55;
N, 8.71. Found: C, 59.66; H, 3.54; N, 8.69%.
1-Phenyl-4,5-dibromo-2-(2-pyridyl)imidazole (13). White
solid, 5.5 g, 72%, mp 115–116 ꢀC; 1H NMR (400 MHz, d6-DMSO):
d 8.18–8.19 (m, 1H), 7.82–7.91 (m, 2H), 7.48–7.50 (m, 3H), 7.32–
7.37 (m, 2H), 7.26–7.30 (m, 1H); 13C NMR (150 MHz, d6-DMSO):
d 148.4, 147.6, 146.1, 144.6, 137.1, 136.9, 136.0, 129.1, 129.0,
128.9, 128.0, 127.8, 123.6, 122.8, 119.6, 117.0, 113.2, 108.9; anal.
calcd for C14H9Br2N3: C, 44.36; H, 2.39; N, 11.09. Found: C,
44.29; H, 2.39; N, 11.07%.
1-(4-Nitrophenyl)-4,5-dibromo-2-(2-pyridyl)imidazole (14).
Yellow solid, 6.9 g, 81%, mp 151–152 ꢀC; 1H NMR (400 MHz, d6-
DMSO): d 8.35–8.38 (m, 2H), 8.16 (d, J ¼ 4.8 Hz, 1H), 8.01 (d, J ¼
8.0 Hz, 1H), 7.89 (td, J ¼ 7.6, 1.6 Hz, 1H), 7.74–7.78 (m, 2H),
7.29–7.32 (m, 1H); 13C NMR (150 MHz, d6-DMSO): d 148.3,
147.5, 147.1, 145.9, 144.4, 143.0, 141.8, 137.2, 129.7, 129.5,
1-Phenyl-4,5-bis-[2,5-dimethyl-3-thienyl]-2-(2-pyridyl)imid-
azole (L4). White solid, 327 mg, 74%, mp 119–120 ꢀC; 1H NMR
(400 MHz, CDCl3): d 8.29 (d, J ¼ 4.8 Hz, 1H), 7.94 (d, J ¼ 8.0 Hz,
1H), 7.66 (td, J ¼ 7.6, 1.6 Hz, 1H), 7.25–7.27 (m, 3H), 7.05–7.12
(m, 3H), 6.62 (s, 1H), 6.08 (s, 1H), 2.36 (s, 3H), 2.24 (s, 3H), 2.21
(s, 3H), 1.89 (s, 3H); 13C NMR (100 MHz, CDCl3): d 149.9, 148.6,
145.1, 138.0, 136.9, 136.6, 135.3, 134.8, 133.5, 130.9, 128.4,
This journal is ª The Royal Society of Chemistry 2013
RSC Adv., 2013, 3, 24146–24153 | 24151